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StatinPremature babies are particularly vulnerable to brain injury. In this study we focus on cortical brain
damage associated with long-term cognitive, behavioral, attentional or socialization deﬁcits in children
born preterm. Using a mouse model of preterm birth (PTB), we demonstrated that complement compo-
nent C5a contributes to fetal cortical brain injury. Disruption of cortical dendritic and axonal
cytoarchitecture was observed in PTB-mice. Fetuses deﬁcient in C5aR (−/−) did not show cortical
brain damage. Treatment with antibody anti-C5, that prevents generation of C5a, also prevented cortical
fetal brain injury in PTB-mice. C5a also showed a detrimental effect on fetal cortical neuron development
and survival in vitro. Increased glutamate release was observed in cortical neurons in culture exposed to
C5a. Blockade of C5aR prevented glutamate increase and restored neurons dendritic and axonal growth
and survival. Similarly, increased glutamate levels –measured by 1HMRS –were observed in vivo in PTB-
fetuses compared to age-matched controls. The blockade of glutamate receptors prevented C5a-induced
abnormal growth and increased cell death in isolated fetal cortical neurons. Simvastatin and pravastatin
prevented cortical fetal brain developmental and metabolic abnormalities -in vivo and in vitro. Neuro-
protective effects of statins were mediated by Akt/PKB signaling pathways. This study shows that
complement activation plays a crucial role in cortical fetal brain injury in PTL and suggests that comple-
ment inhibitors and statins might be good therapeutic options to improve neonatal outcomes in preterm
birth.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Preterm birth is an important cause of perinatal mortality and mor-
bidity. Between 23 and 32 weeks of pregnancy, the human fetal brain is
at a critical stage of development and vulnerable to injury. 25 to 50% of
infants that were born prematurely experience long-term cognitive,
behavioral, attentional or socialization deﬁcits [1–3]. MRI studies in
preterm infants showed decreased volume in the cerebral cortex, sug-
gesting a role for the cortex in these long term complications [1]. Unfor-
tunately, the mechanisms behind these long term disabilities are still
unclear, preventing therefore the development of diagnostic methods
and therapies.ion, Queen's Medical Research
Edinburgh EH16 4TJ, UK.
rdi).
ights reserved.During pregnancy, the developing brain is particularly susceptible to
ischaemic and inﬂammatory insults, the latter often due tomaternal in-
trauterine inﬂammation/infection. Despite the growing association be-
tween inﬂammation with fetal brain injury [4–6], the mediators and
receptors involved remain unknown.
Using a mouse model of inﬂammation-induced PTB [7,8], we dem-
onstrated that complement activation, in particular C5a, plays a crucial
role in the cervical ripening that leads to PTB [7]. Here, we investigate
if C5a also causes damage in the developing fetal brain cortex in this
model. We focused on the cerebral cortex because cognitive deﬁcits
are by far the dominant neurodevelopmental sequelae in infants born
preterm.
In an attempt to ﬁnd a treatment to prevent fetal cortical brain
damage we studied the effects of complement inhibition in this
model. Furthermore, we hypothesized that statins which prevented
complement-mediated tissue injury in several animal models
[9–11], would also prevent fetal cortical brain developmental
abnormalities.
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2.1. Animals
All housing and experimental procedures were performed in com-
pliance with the UK Home Ofﬁce Animals Scientiﬁc Procedures Act
1986 (Home Ofﬁce project licence number 60/4305).
C57BL/6 from commercial vendors and C5a receptor (C5aR)-deﬁcient
mice, generated by homologous recombination technology, by Dr. Craig
Gerard (Harvard Medical School) [12] were used in all the experiments.
It has been described that subclinical genital tract infections are often as-
sociated with spontaneous preterm birth in women. Thus, we used a
mouse model of spontaneous PTDwhich resembles this clinical scenario
[4]. In this model, mice received LPS (Escherichia coli serotype 055:B5)
(250 μg/mouse) intravaginally on day 15 of pregnancy [4].
This dose showed to induce cervical ripening [4] but not systemic
disease in the mother. It has been documented that the vagina is a
poor route for systemic delivery primarily due to the poor absorption
across the vaginal epithelium [13].
To determine whether LPS administered through the vaginal canal
ascends to the uterus and/or reaches systemic circulation, a group of
mice were administered intravaginal LPS labeled with FITC (Sigma
Chemicals, St Louis, MO). FITC-LPS content in the vagina, cervix, uterine
horns, amniotic ﬂuid and blood was measured 12 h after LPS adminis-
tration with a Perkin-Elmer luminescence spectrometer (San Jose, CA,
USA). A standard curve was constructed by plotting ﬂuorescence
(arbitrary units) against different concentrations of FITC-LPS.
In this model, 100% of the mice deliver preterm before gestational
day 17. The pregnant mice treated with LPS were euthanized 18 to
24 h after treatment. The age-matched control mice, that received
intravaginal saline, were euthanized at the same time point. Amniotic
ﬂuid and fetal brains were collected in the LPS-treated mice and age-
matched controls. To inhibit C5, mice were treated on days 10 and 12
of pregnancywith anti-C5mAb (1 mg, intraperitoneally) [14] ormurine
IgG as a control and on day 15 they received intravaginal LPS.
A group of mice received pravastatin (10 μg/mouse, i.p.) or simva-
statin (20 μg/mouse, i.p.) [9] 24 h before and 2 h after LPS intravaginal
administration. Fetal genotypes (C5aR+/− and C5aR−/−)were deter-
mined by polymerase chain reaction. The primers for C5aRwere obtain-
ed from Applied Biosystems (Foster City, CA).
2.2. Simvastatin and pravastatin solutions
Simvastatin (Sigma Chemical) was prepared as a 4 mg/ml stock.
Brieﬂy 4 mg of simvastatin was dissolved in 100 μl of ethanol and
150 μl of 0.1 N NaOH and incubated at 50 °C for 2 h, then the pH was
adjusted to 7, and the total volumewas corrected to 1 ml. The stock so-
lution was diluted to the appropriate concentration in sterile PBS. Prav-
astatin (Sigma Chemical) was directly dissolved in sterile PBS.
2.3. Measurement of C5a
C5a is rapidly cleaved to the more stable metabolite C5adesArg.
Thus, we measured C5adesArg to estimate C5a levels. C5adesArg levels
in amniotic ﬂuid and fetal brain cortex was measured by sandwich
ELISA as previously described [7,8] using rat anti-mouse C5a and biotin
rat anti-mouse C5a (BD Biosciences Pharmingen). The fetal cortical
brain tissue was isolated using a dissecting microscope.
2.4. Isolation of fetal cortical neurons
Cortical neurons from fetal brains were isolated as described by Kim
and Magrane [15]. After surgical removal of the cerebellum, midbrain
and hippocampus the cortical tissue was sequentially incubated with
trypsin and DNAse to dissociate the neurons. More than 98% of the
cells stained positive for βIII tubulin and negative for GFAP indicatingthat there is no glial contamination. After centrifugation the dissociated
neuronswere resuspended in a neuronal culturemedium [15] and plat-
ed on laminin/polylysine-coated dishes (5 × 105 cells/cm2). These cells
extend their neurites and establish synapses in culture after 10 days in
culture and thus represent an accessible model to study cortical brain
development and evaluate synapses and neuritic networks in vitro
[15]. Using these primary neuronal cultures we investigated the effects
of complement component C5a on brain development by evaluating
neuritic networks formation in vitro and we tested statins as a
therapeutic approach to prevent brain injury. Cortical neurons from
day 16 fetuses were isolated and cultured on coverslips coated with
laminin/polylysine. After 7 days in culture (7 days in vitro (7DIV)) neu-
rons were exposed to different treatments (C5a (100 nM) (C5a),
glutamate (glu) (50 μM), C5aR antagonist peptide (AcPhe[L-ornithine-
Pro-D-cyclohexylalanine-Trp-Arg]) (C5aR-AP) (1 μM) [16], MK-810
(1 μM), LY294002 (50 μM) or only media (control)).
The dose of C5a was selected from dose-response studies (Supple-
mental material). A group of neurons was preincubated with pravastatin
(20 μg/ml) or simvastatin (40 μg/ml) 6DIV and on 7DIV C5a was added
to the media (P + C5a; S + C5a)). A group of control neurons and a
group of neurons preincubated with LY294002 for 12 h were exposed
to pravastatin or simvastatin on 6DIV and on 7DIV C5a was added to
the media. Formation of neuritic networks in each experimental group
was evaluated on 10DIV by immunohistochemistry using BIII tubulin an-
tibodies after ﬁxation with paraformaldehyde 4%. Glutamate release to
the media and viability of neurons were measured on 7DIV, 6 h after
the respective treatment. Glutamate was measured using a commercial
kit (Biovision Incorporated, Milpitas, CA, USA and lactate dehydrogenase
(LDH) activity was determined bymeasuring the linear rate of consump-
tion of NADH absorption (340 nm) during the reduction of pyruvate to
lactate using a spectrophotometer. Caspase-3 activity in isolated cortical
neurons was measured by a ﬂuorometric assay based on the hydrolysis
of acetyl Asp-Glu-Val-Asp 7-amido-4-methylcoumarin (Ac-DEVD-AMC)
by caspase 3, resulting in the release of the ﬂuorescent 7-amino-4-
methylcoumarin (AMC) (Sigma Chemicals, St Louis, MO, USA). After
each treatment, the cortical neurons were lysed with Tris buffer
(50 mol/L Tris–HCL, 1 mmol/L EDTA, and 10 mmol/L EGTA at
pH = 7.4) containing 10 μmol/L digitonin for 20 min at 37 °C. The ly-
sates were subjected to a quick centrifugation at 20,000 ×g and cell-
free supernatants were incubated with Ac-DEVD-AFC, 50 μmol/L) for
1 h at 37 °C. The caspase-3 activity was measured by ﬂorescence using
a microplate reader with excitation at 360 nm and emission at 460 nm.
The caspase-3 activity was expressed as ﬂuorescent units (FUs/mg
protein).
2.5. Proton magnetic resonance spectroscopy studies (1HMRS)
This non-invasive in vivo imaging modality was used to study the
biochemical and metabolic proﬁle in fetal brain during preterm.
All MRI experiments were performed using a 7-T horizontal bore
NMR spectrometer (Agilent, Yarnton, UK), equipped with a high-
performance gradient insert (12-cm inner diameter), maximum gradi-
ent strength 400 mT/m. 18 to 24 h after their respective treatments,
the mice were anesthetized with 1.8% isoﬂuorane in oxygen/air (50/
50,1 L/min) and placed in a cradle (Rapid Biomedical GmbH, Rimpar,
Germany). The rectal temperature and respiration rate were monitored
throughout the experiments, and body temperature was maintained at
37 °C with a heat fan. A birdcage coil (33-mm diameter) was used for
radio frequency transmission and signal reception.
In order to place the spectroscopy voxel (Fig. 2H) in the brain,
good anatomical details are required. To this end, respiration-
gated T2-weighted fast spin echo images (echo train length of 4 or
8) of 1 mm slice thickness in 3 orthogonal directions were collected
with the following parameters: repetition time (TR) ≈ 2500 ms
depending on the respiration rate; effective echo time = 50 ms;
ﬁeld of view = 35 mm × 35 mm; matrix = 192 × 192, 2 signal
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troscopy) sequence was used with VAPOR water suppression, outer
volume suppression and the following parameters: TR = 3000 ms,
TE = 23 ms, number of signal averages = 240 or 480, voxel
size = 2.8 × 2.8 × 2.8 mm. The voxel was positioned in the center
of the fetal brain. Magnetic ﬁeld homogeneity within the voxel was
optimized manually. At the end of the PRESS sequence, low resolu-
tion fast spin echo images were acquired to verify that the voxel lo-
cation hadn't changed due to movement of the fetuses. Spectra
were analyzed using LCModel (http://s-provencher.com/pages/
lcmodel.shtml).
2.6. Immunohistochemistry (IHC)
Fetal brainswere harvested from LPS-treatedmice and age-matched
controls (18 to 24 h after induction of preterm labor) and incubated
overnight in PFA 4%with 10% sucrose for cytoprotection. Fetal brain tis-
sue was then frozen in the O.C.T. compound, and cut into 10 μm sec-
tions. A list of the antibodies and their respective dilutions used for
IHC is shown in Table 1. The FITC staining was quantiﬁed using NIS-
Elements Research Imaging software (Nikon Inc. Tech Co., Ltd., Tokyo,
Japan). Exposure timewasﬁxed and the camera settingswere kept con-
stant. The cortical brain tissue was segmented based on red/green/blue
intensity, and the areawas restricted to eliminate debris.Measurements
data per areawere calculated using the following parameters: sumden-
sity (the sum of individual optical densities of each pixel in the area
being measured) and mean density (statistical mean of density values
of pixels). NIS-Elements BR (Nikon Inc., Tokyo, Japan) uses density cal-
ibration curves for evaluation of these parameters. 10 views per slide
were analyzed in each experimental condition.
2.7. Apoptosis and neurodegeneration in fetal brain tissue
Apoptosis in the fetal brain cortex frozen sections was evaluat-
ed using caspase-3–protease – involved in cell death in immature
neurons – immunohistochemistry (Table 1).
Neurodegeneration was measured using Fluoro-Jade B (Millipore,
Millerica, MA, USA), a polyanionic ﬂuorescein derivative which sensi-
tively and speciﬁcally binds to degenerating neurons [17]. FluoroJade
B staining was performed on fetal brain frozen sections following the
protocols suggested by the manufacturer.
2.8. Immunoblotting
To investigate the effects of statins on the expression of PKB
and phosphorilated PKB, isolated fetal cortical neurons were incu-
bated on day 6 (6DIV) with pravastatin (20 μg/ml), simvastatin
(40 μg/ml) or just media (control group). 24 h later (7DIV), ex-
pression of PKB and phosphorylated PKB was assessed by WesternTable 1
Antibodies used for immunohistochemical studies and western blotting (WB).
Clone Speciﬁcity Manufactured by
mAb 10/92 Mouse C5aR Hycult biotech
Anti-MAP2 MAP2 Sigma-Aldrich
Anti-NF200 NF-200 Sigma-Aldrich
Ab 18207 BIII tubulin Abcam
Ab 44976 Caspase-3 Abcam
11E7 Akt (pan) Cell Signaling
(D9E) XP Phospho-Akt (Ser473) Cell Signaling
ICN = isolated cortical neurons; CHEM = chemiluminescence; WB = Western Blot.blotting. Cortical cells were homogenized in ice-cold lysis buffer
(50 mmol/L Tris, pH 7.4, 0.27 mol/L sucrose, 1 mmol/L sodium
orthovanadate, pH 10, 1 mmol/L EDTA, 1 mmol/L EGTA, 10 mmol/L
sodium β-glycerophosphate, 50 mmol/L NaF, 5 mmol/L sodium pyro-
phosphate, 1% [w/v] Triton X-100, 0.1% [v/v] 2-mercaptoethanol, one
tablet of complete TM protease inhibitor [Roche, Burgess Hill, U.K.]),
and 50 μg of protein were run on 4–12% Bis–Tris gels for Western
blotting. Protein signalswere visualized using enhanced chemilumines-
cence (Pierce Biotechnology, Rockford, IL) by exposure to an Amersham
HyperﬁlmTH ECL ﬁlm (Amersham). The antibodies used are described
in Table 1.
2.9. Statistical analysis
Data are expressed as mean ± SD. Statistical differences between
groups were determined using one-way ANOVA with subsequent
two-tailed Student t test.
3. Results
3.1. Intravaginal administration of LPS does not reach systemic circulation
Our results show that 85 ± 2% of the LPS dose administered
intravaginally remained in the cervix 12 h after LPS administration.
Only 13 ± 4% of the administered LPS-FITC dose was found in the am-
nioticﬂuid. The levels of LPS-FITC in systemic circulationwere undetect-
able, suggesting that intravaginal LPS ascends to the cervix but it is not
absorbed to systemic circulation. This is in agreement with the absence
ofmaternal systemic disease (fever, piloerection and lethargy) observed
in pregnant females that received intravaginal LPS. In addition, after giv-
ing birth prematurely the females survive without any health complica-
tions. The offspring – born around day 16 – die because of the effects of
immaturity. Mice born at day 16 are equivalent to extremely preterm
humanbabies (b28 weeks) according to theWorldHealthOrganization
classiﬁcation. Children born very preterm are reported to have an in-
creased frequency of social, emotional, and behavioral problems at
school age compared with their peers born at term [18].
3.2. Fetal brain cortical abnormalities in LPS-treated mice
Fetal brains were harvested 18 to 24 h after the induction of PTB
with intravaginal LPS. The mice that were euthanized showed signs of
preterm labor (vaginal bleeding and cervical dilatation). Immunohisto-
chemical resultswere compared to agematched-control fetuses. Micro-
tubule associated protein-2 (MAP-2) was used as a marker of intact
neuronal cell bodies and neuroﬁlament 200 (NF200) was used to eval-
uate dendritic and axons structure. Decreased staining for NF200 and
MAP-2 was observed in the cortex of fetuses born preterm compared
to age-matched controls (Fig. 1A) (staining intensity (arbitrary units):Dilution Used in Developed with
1/50 Fetal brain Anti-rat-
HRP/DAB
1/100 Fetal brain Anti-rabbit
FITC
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MAP-2: age-matched control = 287 ± 34, PTB (LPS) = 73 ± 22*,
*different from age-matched control, p b 0.01), suggesting a disruption
of cortical dendritic and axonal cytoarchitecture at this stage of fetal cor-
tical brain development. Increased cell death was observed in the fetal
brain cortex in the PTB-model. The number of neurons expressing active
caspase-3 – involved in cell death in immature neurons –was higher in
the fetal brain cortex from fetuses in the PTB group compared to age-
matched controls (Fig. 1A, B).
3.3. Metabolic abnormalities in fetal brains in PTB mice— proton magnetic
resonance spectroscopy (1HMRS) studies
1HMRS was used to assess themetabolic proﬁle of fetal brains in the
uterus. Fetal brain 1HMRS studies were performed in the LPS-treated
mice that showed signs of preterm labor (vaginal bleeding and cervical
dilatation) and in age matched controls. Fig. 1C shows the voxel place-
ment in the fetal brains. A 1HMRS spectrum of a control mouse fetal
brain is represented in Fig. 1D. Four metabolic peaks can be easily iden-
tiﬁed in the spectrum: creatine plus phosphocreatine (Cr), choline-
containing compounds (Cho), N-acetylaspartate (NAA) and lipids. In
addition more complex peaks from glutamate (Glu) can be identiﬁed
(Fig. 1D). The 1HMRS signal from creatine (measure of the global
brain function or integrity) was used to normalize the signals from
other metabolites measured within the same voxel. A signiﬁcant in-
crease in Glutamate/total Creatine (Glu/tCr) but not in other metabo-
lites was observed in the fetal brains from pregnancies complicated byFig. 1. Fetal cortical brain injury in preterm birth. A — Fetal brains sections from LPS-treated mic
(marker for axons), anti-microtubule associated protein 2 (MAP-2) (marker for mature neurons)
in the fetal brains in LPS-treated mice suggests a disruption of cortical dendritic and axonal cytoa
in LPS-treatedmice compared to controls. B— Active caspase-3-positive cells per view-ﬁeld in the
C— The spectroscopy voxel (2.8 × 2.8 × 2.8 mm)was positioned in the center of the fetal brain in
fetal brain from a control mouse showing the different metabolic peaks Cr (creatine), Cho (cholin
chemical species are expressed in parts per million (ppm). E— Table showing the different meta
pared to controls. F— FluoroJade B, high afﬁnity ﬂuorescentmarker for the localization of neuronal
trols. Increased number of Fluorojade B positive cells in the fetal cortical brain in LPS-treated micepreterm birth compared to those of age-matched controls (Fig. 1E). It
has been suggested that excessive signaling by excitatory glutamate
can cause excitotoxicity leading to cell injury and death [19]. Given
the claimed relation between glutamate overexcitatory effects and cell
death we investigated neurodegeneration using FluoroJade B, a marker
for neurons that undergo cell death presumably by excitoxicity [20]. A
Signiﬁcant increase of FluoroJade B positive cells was observed in the
cortex of fetuses in the PTB-model (Fig. 1F). The combinedMRI and his-
tochemical results suggest that fetal cortical brain injury could be
caused by glutamate excitotoxicity.
3.4. C5a is required for fetal brain injury in preterm fetuses
Knowing that complement activation plays a crucial role in this
model of PTB [7,8]wewent on to study complement activation in brains
from the fetuses born prematurely. Increased levels of complement split
product C5a was observed in the amniotic ﬂuid and fetal brains in PTB-
mice compared to those of appropriate controls (Fig. 2A). C5a receptors
were identiﬁed in fetal cortical neurons by immunohistochemistry
(Fig. 2B). Prompted by theseﬁndings,we investigated if C5a could be in-
volved in the cortical fetal brain injury observed in fetuses that are born
preterm. To answer this question we mated C5aR+/− mothers with
C5aR−/− mice to generate C5aR−/− fetuses. Next, we induced pre-
term delivery in C5aR+/− pregnant females and cortical fetal brain
damage was assessed in the resulting C5aR+/− and C5aR−/− fetuses
in the litter. Interestingly C5aR+/− females deliver preterm as wild
type mice and C5a levels in fetal brains after LPS treatment weree (n = 6) and age-matched controls (n = 7) were stained with anti-ﬁlament 200 (NF200)
and anticaspase-3 (marker of apoptotic neurons). Decreased staining for NF200 and MAP-2
rchitecture. Increased number of caspase-3 positive cells is also observed in the fetal cortex
fetal cortical brain in the LPS and control group (means.d.). Original magniﬁcation = ×400.
respiration-gated T2-weighted fast spin echo images. D— 1HMRS spectrum obtained from a
e), Glu (glutamate), N-acetyl-aspartate (NAA), lipids and lactate. Resonant frequencies of the
bolic peaks. Increased glutamate/Cr was observed in fetal brains from LPS-treated mice com-
degeneration, staining in the cortex of fetal brains in LPS-treatedmice and age-matched con-
.
Fig. 2. Role of C5a in fetal cortical brain injury in preterm birth. A— Complement split product C5a in amniotic ﬂuid and fetal cortical brain in LPS-treated mice and age-matched
controls. B — Immunohistochemical detection of C5aR on fetal cortical brain in mice. C5aR−/− mice were used as negative control. C — NF200 staining in the brain cortex of
C5aR+/− and C5aR−/− fetuses in LPS-treated mice. NF200 and MAP-2 staining in the brain cortex in fetuses from mice treated with LPS + antiC5 antibody. D — NF200 and
MAP-2 staining in the fetal brain cortex of LPS-treated mice treated with antibody antiC5.
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C5aR−/− fetuses, but not C5aR+/− fetuses in LPS-treated mice
showed conserved axonal and dendritic architecture at this stage of
development, judged by NF200 staining, comparable to age-
matched controls staining (intensity (arbitrary units): NF200: LPS
(C5aR+/−) = 45 ± 13*, LPS (C5aR-/−) = 198 ± 26*; *differentFig. 3.Role of glutamate in C5a-inducedneurotoxicity in vitro. A—Neuritic network formation in
identiﬁed as neurons by positive BIII tubulin staining. B—Graph bar shows length of axons in isol
glutamate + MK-801, C5a + MK-801). *Different from untreated, p b 0.01. Five to six cortical n
supernatants of fetal cortical neurons incubated under different conditions (A). D — Cell death in
lactate dehydrogenase (LdH) –marker of membrane integrity – to the media. *Different from u
cortical neurons subjected to different treatments.from C5aR+/−, p b 0.01) (Fig. 2C). In support of the role of C5a in cor-
tical fetal brain injury, treatment with antibody anti-C5 – that blocked
generation of C5a – prevented cortical fetal brain abnormalities in LPS-
treated mice. Staining for NF200 and MAP-2 in fetal brains from
antiC5 + LPS treated mice was not different from that of the age-
matched controls (staining intensity (arbitrary units): NF200: age-isolated fetal cortical neurons incubatedwith C5a, glutamate andC5a + C5aR-AP. Cellswere
ated cortical neurons incubated under different conditions (C5a, glutamate, C5a + C5aR-AP,
eurons preparations were used for each experimental condition. C—Glutamate levels in the
isolated cortical neurons subjected to different conditions was measured by the release of
ntreated, p b 0.05 (n = 5/experimental condition). E — Fluorometric caspase 3 activity in
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23; MAP-2: age-matched control = 287 ± 34, LPS = 73 ± 22*,
antiC5 + LPS = 268 ± 32; *different from age-matched control,
p b 0.01), suggesting appropriate axonal and dendritic structure
(Fig. 2D).
3.5. Neurotoxic effects of C5a
To conﬁrm the detrimental effects of C5a on the developing fetal
brain we studied isolated cortical neurons from day 16 fetuses. Immu-
nohistochemical procedures determined that most cultured cells
(N95%) express βIII tubulin (Fig. 3A), protein associated with cortical
neurons and not found in glial cells. These cells extend their neurites
and establish synapses becoming mature neurons after 10 days in cul-
ture (10DIV). To study the effects of C5a on developing neurons
in vitro we exposed the cells on 7DIV to C5a. As a quantitative measure
of neuronal injury during neuronal development, we analyzed the
growth of projections that emanated from the neuronal cell bodies. At
day 10, long axons were observed in cultured control cortical neurons
while the length of axons in C5a-exposed neurons was considerably re-
duced after the addition of C5a to the media on 7DIV (Fig. 3A, B). The
blockade of C5a increased the numbers of dendrites and the length of
axons compared to neurons incubatedwith only C5a (Fig. 3A, B). Axonal
and dendritic architecture in C5aR-AP treated cells was comparable to
control cells (Fig. 3A). Increased levels of glutamate were measured in
the supernatant of cortical neurons incubated with C5a (Fig. 3C). In ad-
dition, isolated cortical neurons incubated with glutamate showed
disrupted neuronal morphology (shorter axons and dendrites) similar
to cells exposed to C5a (Fig. 3A and B). Addition of the N-methyl-D-
asparate antagonist, MK-801 (dizocilpine maleate) prevented C5a and
glutamate-induced diminished axonal length (Fig. 3B). This raises the
possibility that C5a neurotoxicity might be mediated by glutamate
excitotoxicity. Excitation resulting from stimulation of the ionotropic
glutamate receptors is known to cause neuronal apoptosis [19]. Thus,
we looked for signs of neuronal death/apoptosis. Increased release of
lactate dehydrogenase (LdH), marker of cell injury and death, wasFig. 4. Statins prevent fetal cortical brain injury invivo. A—NF200 andMAP-2 staining in the cor
and ﬂuorojade staining in the fetal brain cortex of control, LPS-, LPS + S and LPS + P-treatedm
mice. D — Table showing the different metabolic peaks values measured by 1HMRS of the fetalobserved in cortical neurons cultures exposed to C5a or glutamate
(Fig. 3D). The addition of C5aR-AP and MK-801 prevented C5a-
induced increased cell injury and death (Fig. 3D).
The ﬂuorometric assay of caspase 3 activity showed that there was a
signiﬁcant difference in activity between the control cells and the cells
incubated with C5a and glutamate (p b 0.001) (Fig. 3E). Caspase
activity in control neurons averaged 14 ± 5 FU/mg protein (Fig. 3E).
In contrast, cortical neurons incubated with C5a or glutamate had a sig-
niﬁcantly higher caspase activity, a 4.5–5.0 times increase over controls.
Caspase activity was reduced in cortical neurons incubated with C5a
plus C5aR-AP or MK-801 when compared to cells incubates with C5a
or glutamate alone (Fig. 3E).3.6. Pravastatin and simvastatin prevent brain injury in PTL
Statins showed beneﬁcial effects in several neurological disorders
[16–18]. Thus, we hypothesized that statins could prevent fetal cortical
brain injury in ourmousemodel of PTB. In accordancewith our hypoth-
esis, the disruption in cortical neuron cytoarchitecture observed in the
fetal brains from the PTB mice was not observed when the mice were
pretreated with pravastatin or simvastatin (Fig. 4A). Robust staining
for NF200 and MAP-2 was observed in the cortex of the fetal brains
from the simvastatin + LPS (S + LPS) and the pravastatin + LPS
(P + LPS)-treatedmice, comparable to age-matcheduntreated controls
(Fig. 4A) (staining intensity (arbitrary units: NF200: age-matched
control = 238 ± 45;=S + LPS = 251 ± 32, P + LPS = 228 ± 61;
MAP-2: age-matched control = 247 ± 49, S + LPS = 271 ± 43, P +
LPS = 228 ± 29)). Themice treatedwith LPS andpravastatin or simva-
statin also showed a decreased number of caspase-3 positive cells in the
fetal cortical brain compared to the LPS-treated mice (number positive
cells/view ﬁeld: LPS = 21 ± 3, S + LPS = 4 ± 1, P + LPS = 5 ± 2,
age-matched untreated control = 3 ± 1) (Fig. 4B). A decreased num-
ber of FluoroJadeB positive cells was observed in the fetal brains in
mice treatedwith LPS + statins, suggesting a protective effect of statins
against cell death and neurodegeneration (Fig. 4B). Reduced levels oftex of fetal brains in LPS + P- and LPS + S-treatedmice. n = 5–7 mice/group. B—Caspase
ice. C— C5a levels (ng/mg) in fetal brains from control, LPS-, LPS + S and LPS + P-treated
brains. *Different from age-matched control, p b 0.01.
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(Fig. 4C).
The protective effects of statins were also observed in the 1HMRS
studies. Spectroscopymetabolic studies revealed a signiﬁcant reduction
in glutamate signal in mice treated with simvastatin plus LPS when
compared to mice that only received LPS (Fig. 4D).
We then investigated if statins could prevent C5a-induced toxicity in
developing neurons. Isolated cortical neurons incubatedwith simvastatin
or pravastatin + C5adid not showabnormal dendrite and axon architec-
ture (Fig. 5A). Axons in cortical neurons incubated with statins and C5a
were longer than in cells incubated with only C5a and the axon length
was comparable to control neurons (Fig. 5B). In addition, statins
also prevented C5a-induced increased release of glutamate and Ldh (Glu-
tamate (nmol/ml): control (n = 5): 2.9 ± 0.2; C5a (n = 5):5.9 ± 0.5*;
S + C5a (n = 6):2.8 ± 0.2; P + C5a (n = 5):3.3 ± 0.4; LdH (mU/ml):
control (n = 5):17 ± 6; C5a (n = 5): 53 ± 13*, S + C5a (n = 5):20 ±
8, P + C5a (n = 5):23 ± 6; *different from control, p b 0.01). Further-
more, statins diminished caspase-3 activity in isolated cortical neurons
exposed to C5a (Fig. 5C).
Akt/PKB signaling pathway was reported to be a crucial mechanism
in the beneﬁcial effects of statins in neuronal injury models [21,22].
Thus, we looked into this mechanism in our in vitro model. In agree-
ment with these studies, we observed increased PKB phosphorylation
in cortical neurons incubated with simvastatin or pravastatin (Fig. 5D,
E) compared to untreated cells. Treatment with the PKB/Akt inhibitor
LY294002 blocked the neuroprotective effects of simvastatin and prav-
astatin in C5a-induced neurotoxicity on cortical cells (Fig. 5B),
conﬁrming that the beneﬁcial effects of statins on cortical neuronFig. 5. Statins prevent fetal cortical brain injury in vitro. A— Pravastatin (P) and simvastatin (S) re
graphs represent one of ﬁve similar experiments. Cortical neuronswere identiﬁed by BIII tubulin (
P + C5a andS + C5a, LY294002 + P + C5a, LY294002 + S + C5a and justmedia. *Different fro
caspase 3 activity in cortical neurons incubated with C5a, and C5a plus statins. D— Expression of
incubatedwith simvastatin (S) (lanes 3 and 7), pravastatin (P) (lanes 2 and 6) and onlymedia (–)
mean ± SD).development are dependent on protein kinase B (PKB) signaling. Corti-
cal neurons incubatedwith LY294002 plus statins showed abnormal ax-
onal growth in response to C5a comparable to cells treated with C5a
alone (Fig. 5C).
4. Discussion
Prematurity is an important cause of neonatal brain injury and long-
term neurodevelopmental disabilities. Unfortunately, the mechanisms
behind fetal brain injury are still unclear, preventing therefore the de-
velopment of diagnostic methods and therapies. In this study we dis-
covered the complement system as a crucial mediator in cerebral
cortex injury in fetuses born preterm.
Using amousemodel of preterm birth triggered by a subclinical vag-
inal inﬂammation/infection, we found that C5a is neurotoxic on fetal
cortical neurons.
The presence of fetal brain abnormalities in our mouse model em-
phasizes the validity of our approach to use a mousemodel that resem-
bles the clinical scenario in extremely preterm (b28 weeks) human
babies and allowed us to identify the mediators/effectors of brain dam-
age and test potential therapies. Cortical brain injury, characterized by
abnormal cytoarchitecture of axons and dendrites in neurons and in-
creased cell death, was observed in preterm fetuses but not in age-
matched controls. The presence of cortical brain damage/neuronal
death in LPS-treated mice that deliver preterm and not in age-
matched controls suggests that prenatal exposure to inﬂammation
may have detrimental effects on neurological development in addition
to the termination of the intrauterine environment. The absence ofstore axonal development of isolated cortical neurons incubated with C5a. The microphoto-
positive staining condition). B— Axon length in isolated cortical neurons incubatedwith C5a,
muntreated, p b 0.05 (n = 5cortical neurons preparations/experimental). C— Fluorometric
PKB and phosphorylated PKB was assessed by Western blotting in isolated cortical neurons
(lanes 1 and 5). E—Western blots (n = 3)were quantiﬁed by densitometry (arbitrary units,
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fetuses deﬁcient in C5aR and the toxic effects of C5a in vitro suggest
that C5amay be responsible for the fetal cortical brain damage observed
in fetuses born prematurely. Moreover, increased C5a levels were found
in amniotic ﬂuid and fetal cortical brains in mice that delivered preterm
[7]. Interestingly, Soto et al demonstrated increased C5a levels in amni-
otic ﬂuid in women with spontaneous preterm labor [23]. Isolated fetal
cortical neurons showed abnormal architecture and increased death
when incubated with C5a and this effect was blocked by C5aR antago-
nists, conﬁrming the direct neurotoxic effect of C5a. Other authors also
demonstrated the neurotoxic effects of C5a in adults [24,25]. However,
this is the ﬁrst study, to our knowledge, reporting the involvement of
C5a in fetal brain injury. Brain cells can synthesize a full complement
system and also express speciﬁc complement inhibitors [26]. However,
the amount of complement inhibitors in premature newborns is low
relative to term newborns making the fetuses born preterm more sus-
ceptible to complement-mediated brain injury [27].
AlthoughC5a is traditionally considered a proinﬂammatorymolecule,
several studies have demonstrated its role in the development and sur-
vival of neurons [28,29]. However, C5a inhibits apoptosis in isolated cor-
tical neurons at lower concentrations than those used in experiments
showing its neurotoxic pro-death effects [28,30]. The physiological rele-
vance of high and low doses remains to be established.
Excessive signaling by excitatory neurotransmitter glutamate can be
deleterious to neurons and cause disease [22]. SpectroscopyMRI studies
showed increased glutamate levels in total brain from premature fe-
tuses. In addition, increased reactivity with FluoroJade B – a marker
for neurons that undergo cell death by excitotoxicity – was observed
in fetal cortical brain in mice with LPS-induced preterm birth. That
C5a induces glutamate release from isolated cortical neurons suggests
that C5a-induced cortical brain injury in premature fetuses may be me-
diated by glutamate excitotoxicity. The blockade of glutamate receptors
prevented C5a-induced abnormal cortical neurons development and in-
creased cell death in vitro, conﬁrming the role of glutamate in C5a-
induced neurotoxic effects.
In addition to complement inhibition with antibody anti-C5, statins
prevented cortical brain injury in fetuses from the LPS-treated mothers.
Statins also prevented C5a-induced cortical neuron toxicity in vitro.
Pravastatin and simvastatin restored the cortical brain morphology
andprevented glutamate release and cell death in cortical neurons incu-
bated with C5a. Diminished glutamate levels were also measured in
fetal brains of LPS + simvastatin-treated mice by MRI spectroscopy. It
has been described that a decrease in the level of membrane cholesterol
can result in attenuated transporter-mediated glutamate release from
nerve terminals. Therefore, lowering cholesterol may be used in neuro-
protection in brain injury associated with an increase in glutamate up-
take [31]. Lower levels of C5a were measured in fetal brains from
statins + LPS treated mice compared to mice treated with LPS alone.
It has been described that statins increase the expression of comple-
ment inhibitor DAF and thus block C5a generation [32].
It was suggested that the neuroprotective effects of statins aremedi-
ated by activation of the Akt/PKB signaling pathway [21,22] and that
this pathway increases neuronal resistance to glutamate-induced apo-
ptosis [33]. Our studies show increased phosphorylation of PKB and di-
minished fetal neuronal death in statin-treated mice. It is likely that the
protective effects of statins can be caused by an increased resistance to
glutamate through PKB signaling. The role of PKB in the protective ef-
fects of statinwas conﬁrmed by the observation that statins did not pro-
tect cortical fetal neurons from C5a-induced injury when neurons were
previously treated with PKB/Akt inhibitor LY294002. Our studies were
focused on the cortical neurons. However, we also need to consider
the potential effects of inﬂammation/complement activation on other
cells in the central nervous system like glial cells and astrocytes that
can also contribute to fetal brain damage in prematurity.
In conclusion,we demonstrated a previously unknown role for com-
plement anaphylotoxin C5a in cortical brain abnormal developmentand increased cell death in preterm fetuses. These data together with
our previous observations that C5a induces cervical ripening and that
complement activation does not play a role in term parturition [8] sug-
gest that the complement system might be a good target for therapy to
prevent fetal cortical brain damage and preterm birth. We also found
that statins prevented C5a-induced disruption of cortical dendritic and
axonal cytoarchitecture. Because statins are already approved for thera-
peutic use and proved not to be harmful to the fetus [34], our studies if
translatable to women in clinical trials may provide a safe and fast way
to prevent fetal cortical brain injury and the resulting long-term
neurodevelopmental disabilities.
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